<DOC>
	<DOCNO>NCT00002974</DOCNO>
	<brief_summary>RATIONALE : Hyperthermia therapy kill tumor cell heat several degree body temperature . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy whole-body hyperthermia may kill tumor cell . PURPOSE : Phase II trial study effectiveness whole-body hyperthermia plus combination chemotherapy treat patient advanced sarcoma metastatic surgically remove .</brief_summary>
	<brief_title>Whole-Body Hyperthermia Plus Chemotherapy Treating Patients With Advanced Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate combination 41.8 degree Celsius whole body hyperthermia ( WBH ) ifosfamide/carboplatin/etoposide ( ICE ) chemotherapy patient advance sarcoma . II . Assess efficacy combination therapy . III . Assess clinical toxicity WBH ICE patient . IV . Obtain pilot data effect WBH ICE cytokine induction patient . OUTLINE : Treatment whole body hyperthermia ( WBH ) ifosfamide/carboplatin/etoposide ( ICE ) give every 3-4 week . On day 1 treatment , ifosfamide administer intravenously 60 minute begin hyperthermia . Carboplatin administer intravenously 20 minute maximum temperature . Etoposide administer intravenously 60 minute receive hyperthermia day 2 3 hyperthermia . Patient disease status reevaluate 2 course . If disease progression , treatment continue maximum 4 course . PROJECTED ACCRUAL : Approximately 17-34 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced sarcoma metastatic incurable surgically Evaluable measurable disease Must refractory know form effective therapy No CNS tumor involvement No major liver involvement ( 33 % replacement liver tumor ) PATIENT CHARACTERISTICS : Age : 1865 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC great 3,000/mm3 Absolute granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Alkaline phosphatase great 3 time normal SGOT great 3 time normal Protein le 15 % low limit normal Renal : BUN le 30 mg/dL Creatinine le 1.5 mg/dL OR Creatinine clearance le 60 mL/min Calcium great 11.0 mg/dL Sodium 130150 mmol/L Potassium 3.05.0 mmol/L Cardiovascular : No organic heart disease coronary artery disease history angina history dysrhythmia require ongoing medical intervention uncontrolled hypertension patient require beta blocker congestive heart failure Neurologic : No tumor involvement CNS No moderate severe peripheral neuropathy No history severe emotional instability psychiatric history Pulmonary : FEV1 least 60 % predict Maximum voluntary volume least 60 % predict Partial pressure oxygen least 60 OR Oxygen saturation least 90 % Other : No history secondary primary cancer conceivably could active No active nonmalignant gastric and/or duodenal ulcer No serious infection require hospitalization within previous 14 day No history hepatitis relate general anesthesia No history allergy lidocaine relate compound No development malignant hyperthermia general anesthesia No unexplained persistent fever Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 8 week since nitrosoureas ( e.g. , CCNU , BCNU , mitomycin ) At least 4 week since chemotherapy Recovered toxic effect Endocrine therapy : Not specify Radiotherapy : No prior irradiation 25 % marrow Surgery : Not specify Other : No concurrent nonsteroidal antiinflammatory agent aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>